

7-Deazaadenines: synthesis of some new pyrrolo[2,3-*d*]-pyrimidin-4-amines

Abolghasem Davoodnia · Maryam Khashi ·
Niloofer Tavakoli-Hoseini · Raheleh Moloudi ·
Hassan Ali Zamani

Received: 4 October 2011 / Accepted: 22 August 2012 / Published online: 28 September 2012
© Springer-Verlag 2012

Abstract New 2-aryl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amines (derivatives of 7-deazaadenine) were prepared through cyclocondensation of 2-amino-1*H*-pyrrole-3-carbonitriles with aryl nitriles in the presence of potassium *t*-butoxide in boiling *t*-butanol. All synthesized compounds were characterized on the basis of their spectral and microanalytical data.

Keywords 2-Amino-1*H*-pyrrole-3-carbonitriles ·
Aryl nitriles · 7-Deazaadenines ·
Pyrrolo[2,3-*d*]pyrimidin-4-amines

Introduction

In the last few decades, the chemistry of pyrrole and fused heterocyclic pyrroles has received considerable attention owing to their synthetic and effective biological importance [1–3]. Because of the presence of a pyrrolo[2,3-*d*]pyrimidine moiety in some important antibiotics [4–6] and their structural resemblance to purines (**A**), interest has arisen in the construction of such compounds. Moreover, these compounds have been reported to possess significant anti-HIV [7], antitumor [8], antimicrobial [9], and antiangiogenic [10] activities. Pyrrolo[2,3-*d*]pyrimidin-4-amines (**C**) may be regarded as analogues of adenine (**B**) in which its *N*-7 (purine numbering) has been replaced by a CH

group and therefore can be named as 7-deazaadenines. A number of these compounds are known to show anti-inflammatory [11], antifungal [12], and antibacterial [12] activities. Also, some 4-substituted aminopyrrolo[2,3-*d*]pyrimidine derivatives are selective A₁-adenosine receptor antagonists [13] (Fig. 1).

These findings encouraged us to synthesize some new 7-deazaadenine derivatives. Therefore, in continuation of our previous works in the synthesis of new heterocyclic compounds with potential biological activities [14–30], in this paper we report a convenient synthesis of new 2-aryl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amines (derivatives of 7-deazaadenine) **3a–3f** by reaction of 2-amino-1*H*-pyrrole-3-carbonitriles **1a–1c** [31] with aryl nitriles **2a–2c** in the presence of potassium *t*-butoxide in boiling *t*-butanol (Scheme 1).



Results and discussion

Cyclocondensation of 2-amino-1*H*-pyrrole-3-carbonitriles **1a–1c** with aryl nitriles **2a–2c** in the presence of potassium *t*-butoxide in *t*-butanol under reflux gave products identified as 2-aryl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-amines **3a–3f** (Table 1). The structures of new compounds **3a–3f** were deduced from their spectral and microanalytical data. For example, the ¹H NMR spectrum of **3d** in CDCl₃ did not show the NH₂ signal at $\delta = 4.06$ ppm belonging to the precursor **1b**, but instead showed a broad 2H signal at 5.05 ppm for an NH₂ group as well as a sharp 3H signal at 2.50 ppm for methyl protons indicating the formation of the bicyclic compound **3d**. The IR spectrum was devoid of the CN absorption band at 2,191 cm^{−1} of the precursor, which shows the inclusion of the nitrile moiety in the cyclocondensation process. Also this compound gave

A. Davoodnia (✉) · N. Tavakoli-Hoseini · R. Moloudi ·
H. A. Zamani
Department of Chemistry, Mashhad Branch,
Islamic Azad University, Mashhad, Iran
e-mail: adavoodnia@yahoo.com; adavoodnia@mshdiau.ac.ir

M. Khashi
Young Researchers Club, Mashhad Branch,
Islamic Azad University, Mashhad, Iran

Fig. 1 Purine core (A), adenine (B), and its 7-deaza analogue (C)



Scheme 1

Table 1 Synthesis of 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-amines **3a-3f** (Scheme 1)

Entry	R	Ar	Product	Time/h	Yield/% ^a	M.p./°C
1	Methyl	C ₆ H ₅	3a	6	71	232–233
2	Cyclohexyl	C ₆ H ₅	3b	8	79	206–207
3	Cyclohexyl	4-ClC ₆ H ₄	3c	8	67	207–209
4	Cyclohexyl	3-MeC ₆ H ₄	3d	8	66	261–262
5	Benzyl	C ₆ H ₅	3e	7	72	245–247
6	Benzyl	3-MeC ₆ H ₄	3f	7	65	164–167

^a Isolated yields

satisfactory elemental analysis data corresponding to the molecular formula C₃₁H₃₀N₄. The formation of the products **3a-3f** is assumed to proceed via the intermediates **4** prepared by initial nucleophilic attack of the amino group in the 2-position of pyrrole on the cyano group of aryl nitriles. However, under these conditions, attempts to isolate these intermediates failed after careful monitoring of the reactions.

In conclusion, we have reported a facile synthesis of some new pyrrolo[2,3-d]pyrimidin-4-amines (7-deazaadenines) in good yields by cyclocondensation of 2-amino-1H-pyrrole-3-carbonitriles with aryl nitriles in the presence of potassium *t*-butoxide in boiling *t*-butanol.

Experimental

Melting points were recorded on a Stuart SMP3 melting point apparatus. The IR spectra were obtained using a Bruker Tensor 27 spectrophotometer from KBr disks. ¹H NMR (500 MHz) spectra were recorded with a Bruker 500 MHz spectrometer. ¹³C NMR (100 MHz) spectra were recorded with a Bruker 400 MHz spectrometer. Mass spectra were obtained using a Finnigan-MAT 8430 mass spectrometer operating at an ionization potential of 70 eV. Elemental analysis was performed on a Thermo Finnigan Flash EA microanalyzer.

General procedure for the preparation of 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-amines **3a-3f**

To a solution of 5 mmol 2-amino-1H-pyrrole-3-carbonitriles **1a-1c** and 1 mmol potassium *t*-butoxide in 25 cm³ *t*-butanol, 5.5 mmol aryl nitriles **2a-2c** was added. The reaction mixture was heated under reflux for 6–8 h. The reaction was monitored by TLC. Upon completion, the solvent was evaporated in vacuo, the residue was dissolved in 25 cm³ water, and subsequently neutralized by 1 N HCl. The crude product was collected and recrystallized from

ethanol to give compounds **3a–3f** in 65–79 % yields (Table 1).

7-Methyl-2,5,6-triphenyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (3a, C₂₅H₂₀N₄)

¹H NMR (500 MHz, CDCl₃): δ = 3.84 (s, 3H, CH₃), 5.15 (s, 2H, NH₂), 7.27–7.55 (m, 13H, H_{ar}), 8.50–8.55 (m, 2H, H_{ar}) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 29.87, 100.54, 113.56, 126.86, 127.90, 128.13, 128.29, 128.39, 128.58, 129.30, 130.54, 130.80, 130.87, 134.84, 135.44, 139.22, 152.24, 156.73, 158.16 ppm; IR (KBr): $\bar{\nu}$ = 3,286, 3,162 (NH₂) cm⁻¹; MS: m/z (%) = 376 (M⁺, 71), 257 (15), 256 (22), 214 (14), 189 (12), 118 (14), 104 (88), 91 (19), 77 (100), 69 (37), 57 (62), 55 (62).

7-Cyclohexyl-2,5,6-triphenyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (3b, C₃₀H₂₈N₄)

¹H NMR (CDCl₃): δ = 1.20–2.00 (m, 8H, cyclohexyl), 2.90–3.05 (m, 2H, cyclohexyl), 4.00–4.10 (m, 1H, CH–N), 5.09 (br s, 2H, NH₂), 7.25–7.70 (m, 13H, H_{ar}), 8.53 (d, 2H, *J* = 8.2 Hz, H_{ar}) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 25.60, 26.38, 31.44, 56.81, 101.12, 113.33, 126.67, 127.84, 128.15, 128.25, 128.30, 128.39, 129.18, 130.58, 131.11, 131.55, 135.09, 135.52, 139.41, 151.67, 156.82, 156.87 ppm; IR (KBr): $\bar{\nu}$ = 3,292, 3,169 (NH₂) cm⁻¹; MS: m/z (%) = 444 (M⁺, 92), 362 (100), 259 (16), 257 (16), 241 (21), 214 (12), 128 (10), 104 (36), 83 (12), 77 (18), 67 (14), 57 (9), 55 (31).

2-(4-Chlorophenyl)-7-cyclohexyl-5,6-diphenyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (3c, C₃₀H₂₇ClN₄)

¹H NMR (CDCl₃): δ = 1.20–2.00 (m, 8H, cyclohexyl), 2.85–3.00 (m, 2H, cyclohexyl), 4.00–4.10 (m, 1H, CH–N), 5.04 (br s, 2H, NH₂), 7.20–7.50 (m, 12H, H_{ar}), 8.46 (d, 2H, *J* = 8.6 Hz, H_{ar}) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 25.61, 26.34, 31.46, 56.80, 101.19, 113.35, 126.72, 128.20, 128.31, 128.37, 128.40, 129.13, 130.56, 131.07, 131.43, 134.97, 135.08, 135.68, 137.98, 151.52, 155.89, 156.79 ppm; IR (KBr): $\bar{\nu}$ = 3,306, 3,145 (NH₂) cm⁻¹; MS: m/z (%) = 480 (M⁺+2, 28), 478 (M⁺, 85), 396 (100), 259 (33), 257 (26), 241 (47), 214 (28), 189 (18), 155 (35), 138 (59), 128 (32), 104 (26), 83 (34), 77 (35), 57 (37), 55 (79).

7-Cyclohexyl-2-(3-methylphenyl)-5,6-diphenyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (3d, C₃₁H₃₀N₄)

¹H NMR (CDCl₃): δ = 0.85–1.95 (m, 8H, cyclohexyl), 2.50 (s, 3H, CH₃), 2.90–3.05 (m, 2H, cyclohexyl), 4.00–4.10 (m, 1H, CH–N), 5.05 (br s, 2H, NH₂), 7.20–7.45 (m, 12H, H_{ar}), 8.32 (d, 2H, *J* = 8.0 Hz, H_{ar}) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 21.71, 25.63, 26.39, 31.43, 56.76, 101.08, 113.29, 125.01, 126.64, 128.13, 128.18, 128.29, 128.38, 128.49, 129.96, 130.59, 131.12, 131.58, 135.13, 135.43, 137.68, 139.40, 151.69, 156.83, 157.08 ppm; IR (KBr): $\bar{\nu}$ = 3,304, 3,161 (NH₂) cm⁻¹; MS: m/z (%) = 458

(M⁺, 15), 376 (100), 259 (11), 241 (10), 125 (14), 111 (21), 97 (30), 83 (32), 71 (35), 69 (30), 57 (57), 55 (54).

7-Benzyl-2,5,6-triphenyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (3e, C₃₁H₂₄N₄)

¹H NMR (CDCl₃): δ = 5.16 (s, 2H, NH₂), 5.52 (s, 2H, CH₂), 6.95–7.65 (m, 18H, H_{ar}), 8.60–8.65 (m, 2H, H_{ar}) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 46.14, 100.53, 114.21, 126.86, 127.24, 127.65, 128.01, 128.25, 128.28, 128.38, 128.53, 129.16, 129.35, 130.53, 130.87, 131.22, 134.69, 135.34, 138.35, 139.22, 152.32, 156.91, 158.24 ppm; IR (KBr): $\bar{\nu}$ = 3,285, 3,158 (NH₂) cm⁻¹; MS: m/z (%) = 452 (M⁺, 100), 375 (10), 361 (49), 257 (16), 241 (8), 214 (9), 187 (12), 128 (15), 104 (55), 91 (81), 77 (36), 59 (91), 57 (40).

7-Benzyl-2-(3-methylphenyl)-5,6-diphenyl-7H-pyrrolo[2,3-*d*]pyrimidin-4-amine (3f, C₃₂H₂₆N₄)

¹H NMR (CDCl₃): δ = 2.49 (s, 3H, CH₃), 5.18 (br s, 2H, NH₂), 5.52 (s, 2H, CH₂), 7.05–7.45 (m, 17H, H_{ar}), 8.33 (d, 2H, *J* = 7.0 Hz, H_{ar}) ppm; ¹³C NMR (100 MHz, CDCl₃): δ = 21.65, 46.13, 100.48, 114.18, 125.18, 126.82, 126.83, 127.21, 127.68, 128.22, 128.34, 128.51, 128.56, 128.57, 130.15, 130.51, 130.88, 131.21, 134.69, 135.30, 137.77, 138.36, 139.12, 152.33, 156.81, 158.38 ppm; IR (KBr): $\bar{\nu}$ = 3,305, 3,134 (NH₂) cm⁻¹; MS: m/z (%) = 466 (M⁺, 100), 389 (11), 375 (61), 257 (18), 241 (9), 214 (8), 194 (11), 128 (14), 118 (41), 104 (9), 91 (91), 77 (16), 57 (28), 55 (24).

Acknowledgments The authors express their gratitude to the Islamic Azad University, Mashhad Branch for its financial support.

References

- Baccolini G, Sandali C (1987) J Chem Soc Chem Commun 10:788
- Toja E, Depaoli A, Tuan G, Kettenring J (1987) Synthesis 272
- Basyouni WM, Hosni HM, El-Bayouki KAM (1997) J Chem Res (S) 452
- Taylor EC, Hendess W (1965) J Am Chem Soc 87:1995
- Bayomi SM, Kenneth EP, Sowell JW (1985) J Heterocycl Chem 22:83
- Rao KV (1968) J Med Chem 11:939
- Kim HO, Schinazi RF, Nampalli S, Shanmuganathan K, Cannon DL, Alves AJ, Jeong LS, Beach JW, Chu CK (1993) J Med Chem 36:30
- Acs G, Reich E, Mori M (1964) Proc Nat Sci 52:493
- Mohamed MS, Rashad AE, Zaki MEA, Fatahala SS (2005) Acta Pharm 55:237
- Gangjee A, Namjoshi OA, Yu JM, Ihnat MA, Thorpe JE, Warnke LA (2008) Bioorg Med Chem 16:5514
- Mohamed MS, Kamel R, Fatahala SS (2010) Eur J Med Chem 45:2994
- Hilmy KMH, Khalifa MMA, Hawata MAA, Keshk RMA, El-Torgman A (2010) Eur J Med Chem 45:5243
- Campbell RM, Cartwright C, Chen W, Chen Y, Duzic E, Fu JM, Loveland M, Manning R, McKibben B, Pleiman CM, Silverman L, Trueheart J, Webb DR, Wilkinson V, Witter DJ, Xie XB, Castelhana AL (1999) Bioorg Med Chem Lett 9:2413

14. Rahimizadeh M, Davoodnia A, Heravi MM, Bakavoli M (2002) *Phosphorus Sulfur Silicon Relat Elem* 177:2923
15. Bakavoli M, Davoodnia A, Rahimizadeh M, Heravi MM (2002) *Phosphorus Sulfur Silicon Relat Elem* 177:2303
16. Roshani M, Davoodnia A, Hedayat MS, Bakavoli M (2004) *Phosphorus Sulfur Silicon Relat Elem* 179:1153
17. Davoodnia A, Bakavoli M, Vahedinia A, Rahimizadeh M, Roshani M (2006) *Heterocycles* 68:801
18. Davoodnia A, Bakavoli M, Pooryaghoobi N, Roshani M (2007) *Heterocycl Commun* 13:323
19. Davoodnia A, Roshani M, Saleh-Nadim E, Bakavoli M, Tavakoli-Hoseini N (2007) *Chin Chem Lett* 18:1327
20. Davoodnia A, Zhiani R, Roshani M, Bakavoli M, Bashash M (2007) *Phosphorus Sulfur Silicon Relat Elem* 182:1219
21. Davoodnia A, Momen-Heravi M, Golshani E, Bakavoli M, Dehabadi L (2007) *J Chem Res*, pp 257–258
22. Davoodnia A, Behmadi H, Zare-Bidaki A, Bakavoli M, Tavakoli-Hoseini N (2007) *Chin Chem Lett* 18:1163
23. Davoodnia A, Bakavoli M, Barakouhi G, Tavakoli-Hoseini N (2007) *Chin Chem Lett* 18:1483
24. Davoodnia A, Bakavoli M, Mohseni S, Tavakoli-Hoseini N (2008) *Monatsh Chem* 139:963
25. Davoodnia A, Zhiani R, Tavakoli-Hoseini N (2008) *Monatsh Chem* 139:1405
26. Davoodnia A, Eshghi H, Salavaty A, Tavakoli-Hoseini N (2008) *J Chem Res*, pp 1–2
27. Davoodnia A, Bakavoli M, Zareei N, Tavakoli-Hoseini N (2009) *Bulg Chem Commun* 41:226
28. Davoodnia A, Rahimizadeh M, Atapour-Mashhad H, Tavakoli-Hoseini N (2009) *Heteroat Chem* 20:346
29. Davoodnia A, Bakavoli M, Soleimany M, Tavakoli-Hoseini N (2009) *Monatsh Chem* 140:355
30. Davoodnia A, Bakavoli M, Moloudi R, Khashi M, Tavakoli-Hoseini N (2010) *Chin Chem Lett* 21:1
31. Offermann W, Eger K, Roth H (1981) *J Arch Pharm* 314:168